At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 462 enrolled
Drug / intervention
teneligliptin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Safety Study of MP-513 as Monotherapy or in Combination With Oral Antihyperglycaemic Agent in Japanese Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 3 clinical trial evaluating teneligliptin, glinide, and 2 other interventions for Type 2 Diabetes Mellitus. Completed, enrolled 462 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with oral antihyperglycaemic agent in patients with type 2 Diabetes for 52 weeks administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionSep 2012
TodayJul 2026
First PostedFeb 23, 2011
Enrollment StartFeb 1, 2011
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.4 years ago
Interventions
teneligliptindrug
glinidedrug
biguanidedrug
alpha-glucosidase inhibitordrug